chr10-94942290-C-T
Variant summary
Our verdict is Benign. Variant got -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_000771.4(CYP2C9):c.430C>T(p.Arg144Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.115 in 1,613,772 control chromosomes in the GnomAD database, including 11,971 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign,drug response,other (★★). Another nucleotide change resulting in the same amino acid substitution has been previously reported as Likely benign in UniProt.
Frequency
Consequence
NM_000771.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -12 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0882 AC: 13405AN: 152046Hom.: 755 Cov.: 32
GnomAD3 exomes AF: 0.0920 AC: 23117AN: 251228Hom.: 1356 AF XY: 0.0940 AC XY: 12761AN XY: 135766
GnomAD4 exome AF: 0.118 AC: 171842AN: 1461608Hom.: 11216 Cov.: 33 AF XY: 0.116 AC XY: 84405AN XY: 727126
GnomAD4 genome AF: 0.0881 AC: 13400AN: 152164Hom.: 755 Cov.: 32 AF XY: 0.0870 AC XY: 6471AN XY: 74388
ClinVar
Submissions by phenotype
Warfarin response Other:2
drug response, no assertion criteria provided | literature only | OMIM | Aug 09, 2018 | - - |
drug response, no assertion criteria provided | research | Faculty of Pharmacy, Damascus University | - | rs1799853 is a SNP in the CYP2C9 gene and is linked to poor warfarin metabolism and risk of GI bleeding with warfarin, rs1799853 is associated with reduced enzyme activity and lower clearance rates of warfarin leading to higher rates of warfarin concentration likely responsive |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Mar 09, 2018 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
Piroxicam response Other:1
drug response, criteria provided, single submitter | curation | Medical Genetics Summaries | Feb 11, 2019 | Individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) have reduced clearance of piroxicam. Because the standard recommended dose of piroxicam may cause abnormally high plasma levels, a dose reduction should be considered for these individuals. Poor metabolizer |
Phenytoin response Other:1
drug response, no assertion criteria provided | case-control | Equipe Genetique des Anomalies du Developpement, Université de Bourgogne | Sep 24, 2020 | May cause toxicity/ADR and poor metabolism/PK Decreased CYP2C9 function |
Lesinurad response Other:1
drug response, criteria provided, single submitter | curation | Medical Genetics Summaries | Feb 11, 2019 | Lesinurad should be used with caution in individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) because of increased exposure and an increased risk of side effects. Poor metabolizer |
not provided Other:1
other, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jul 09, 2015 | - Variant classified as "other reportable" ??? variant is clinically benign (not associated with disease) but is reported when observed (e.g. pseudodeficiency alleles). |
Flurbiprofen response Other:1
drug response, criteria provided, single submitter | curation | Medical Genetics Summaries | Feb 11, 2019 | The dose of flurbiprofen should be reduced in individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) to avoid abnormally high plasma levels due to reduced metabolic clearance. Poor metabolizer |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at